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Short title: Zinc and type 2 diabetes mellitus: systematic review and meta-analysis 
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Abbreviations: T2DM, type 2 diabetes mellitus; EURRECA, EURopean micronutrient 
RECommendations Aligned; MD, mean difference; AAS, absorption spectrophotometry; ICP-
MS, inductively coupled plasma mass spectrometry; ICP-AES, inductively coupled plasma 
atomic emission spectrometry. 
Abstract 
The aim of this systematic review, meta-analysis and meta-regression was to examine the 
relationship between type 2 diabetes mellitus (T2DM) and concentration of zinc in whole 
blood, as well as dietary zinc intake. Searches were performed using Ovid MEDLINE, 
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Embase (Ovid) and The Cochrane Library (CENTRAL). Observational studies conducted on 
diabetic and healthy adults, with data on dietary zinc intake and/or concentration of zinc in 
whole blood, were selected. The search strategy yielded 11,150 publications and the manual 
search 6, of which 11 were included in the meta-analyses. Mean difference (MD) and 95% 
confidence interval (CI), were calculated using the generic inverse-variance method with 
random-effects models. Heterogeneity was assessed by the Cochran Q-statistic and 
quantified by the I2 statistic. Meta-regressions and stratified analysis were used to examine 
whether any covariate had influence on the results. The pooled MD for the dietary zinc 
intake meta-analysis was -0.40 (95% CI: -1.59 to 0.79; I2 = 61.0%). Differences between 
diabetic and non-diabetic subjects became significant in the presence of complications 
associated with diabetes (MD = -2.26; 95% CI: -3.49 to -1.02; I2 = 11.9%). Meta-regression 
showed that for each year since the diagnosis of diabetes the concentration of zinc in whole 
blood decreased in diabetic patients regarding healthy controls [MD (concentration of zinc in 
blood) = 732.61 + (-77.88303) x (duration of diabetes in years)], which is not generally 
explained by a lower intake of zinc. 
Highlights 
Duration of T2DM is associated with a reduction in whole blood zinc concentration. 
Dietary zinc intake seems not to explain differences in whole blood zinc concentration. 
Only diabetics with complications seem to consume less zinc than healthy subjects. 
Introduction 
Zinc is an essential trace element that is directly implicated in the physiology of glucose 
metabolism, participating in the synthesis, storage, secretion, action and translocation of 
insulin into the cells [1–3], as well as translocation of GLUT4 to the cell surface for glucose 
transport into the insulin responsive cells [4]. Disturbances in zinc homeostasis may play a 
role in the pathogenesis [5,6], pathophysiology [7–9] and control [10–12] of type 2 diabetes 
mellitus (T2DM). In addition, it has been observed that T2DM patients with a good glycemic 
control had a higher zinc status compared to those with poor glycemic control [13]. T2DM is 
a major global health problem. The prevalence of diabetes worldwide was estimated as 415 
million people aged 20-79 years in 2015, and it has been forecast to increase to 642 million 
in 2040 [14]. 
Several studies [15,16], but not all [17,18], have found a significantly lower concentration of 
zinc in whole blood in patients with T2DM compared with healthy subjects. Although blood 
zinc is not a sensitive biomarker of zinc status, red blood cells are rich in zinc, and changes 
in the concentration of zinc in whole blood may reflect alterations in red blood cell zinc 
transport. It has been proposed that a lower dietary zinc intake in diabetic individuals may 
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explain the reduced plasma and whole blood zinc concentrations observed in some studies 
[19,20]. This seems to  be supported by a dose–response relationship between zinc intake 
and zinc status in adult populations observed in a systematic review and meta-analysis [21]. 
However, differences in dietary zinc intake between patients with T2DM and healthy controls 
have not been confirmed by subsequent studies [22,23]. 
The purpose of this study was to undertake a systematic review, meta-analysis and meta-
regression of the published literature to examine the relationship between T2DM, 
concentration of zinc in whole blood, and dietary zinc intake. 
Material and methods 
This systematic review and meta-analysis was conducted within the framework of the 
EURopean micronutrient RECommendations Aligned (EURRECA) Network of Excellence. It 
has been recorded in PROSPERO (2015: CRD42015020178) and can be consulted here: 
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015020178). The 
implementation of this systematic review and meta-analysis was performed following the 
MOOSE criteria statement [24]. 
Literature search 
The search strategy was performed as part of a wider review process to identify studies 
assessing the effect of zinc on different outcomes. The searches were performed of 
literature published up to and including March 2016 in Ovid MEDLINE, Embase (Ovid) and 
The Cochrane Library (CENTRAL) using search terms for (‘study designs in humans’) AND 
(Zinc) AND (intake OR status). Manual searches of references supplemented the electronic 
search. 
Study selection 
To be included in the research, studies had to be original publications of observational 
design (prospective cohort, case-control, and cross-sectional), conducted on human adults 
(≥18 years) with type 2 diabetes mellitus (T2DM) patients and healthy individuals as 
controls. In addition, included studies needed to report data on the mean and standard 
deviation of dietary zinc intake and/or concentration of zinc in whole blood in both diabetic 
and non-diabetic subjects. Animal and in vitro studies, studies with diabetic participants other 
than T2DM, and study designs other than prospective cohort, case-control, and cross-
sectional studies, were excluded. 
The selection process was carried out in two stages, the first involved filtering studies by 
their title and abstract (Figure 1). In the second stage, potentially relevant studies were 
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explored further using the full text of the article and assessed against the inclusion and 
exclusion criteria. Stages 1 and 2 were carried out by members of the team (JCFC, MWM, 
VHM, CD and NL). A 10% sample was cross checked by a second researcher to ensure 
consistency between reviewers and any discrepancies were resolved by discussion. 
From each article selected for inclusion at stage 2, the following data were extracted into an 
excel spreadsheet: author, publication year, study design, sample size, control matched, 
geographical area, gender, age, BMI (Body Mass Index), complications associated with 
diabetes, duration of T2DM, dietary survey method used to estimate zinc intake, number of 
days of administration of the dietary survey, dietary zinc intake of participants, laboratory 
technique used to determine concentration of zinc in whole blood, and its concentrations 
(Table 1). The extracted data were checked independently by at least two researchers. In 
order to incorporate relevant data from those selected studies that presented results in forms 
other than the mean and standard deviation, such as median and the interquartile range, we 
used the estimation methods proposed by Wan et al. [25]. These methods allowed 
appropriate estimates to be made for both normal data and skewed data. Variables 
expressed as a range, such as age in diabetic and non-diabetic groups, duration of diabetes 
in diabetic subjects, were assigned the midpoint of the range to estimate a mean value. The 
quality of publications (Table S1) was evaluated using the STROBE Statement [26], and the 
score was used in the statistics analyses. If any of the data was missing, the authors were 
contacted for additional data. 
Statistical analysis 
Data were expressed as mean difference (MD) with 95% confidence interval (CI), and 
pooled using the generic inverse-variance method with random-effects models. MD in both 
meta-analyses was calculated as the difference between the values of diabetics and those of 
non-diabetics. Forest plots were created to visualise summary estimates. Heterogeneity was 
assessed by the Cochran Q-statistic and quantified by the I2 statistic, which represents the 
percentage of variation attributable to between‐study heterogeneity [27]. I2 values of 25%, 
50%, and 75% were considered as low, medium, and high heterogeneity, respectively 
[28,29]. Potential sources of heterogeneity in both meta‐analyses were explored by 
univariate meta‐regressions (tables 2 and 3), using covariates such as geographic area, 
eastern (1) vs. western (2); continent, America (1), Asia (2), Oceania (3), and Europe (4); 
gender, men (1) vs. women (2); quality (STROBE Statement [26]), both categorical and 
continuous variables; age of diabetics patients and healthy controls, both categorical and 
continuous variables; BMI category in diabetic and non diabetic subjects, normal weight 
(18.5-24.9 kg/m2) (1) vs. overweight (25.0-29.9 kg/m2) (2), duration of diabetes, both 
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categorical and continuous variables, complications associated with diabetes, without (1) vs. 
with complications (2); sample size, both categorical and continuous variables; matched, yes 
(1) vs. no (2);dietary survey method,  24-hour dietary recall (1) vs. dietary record (2); number 
of days of administration of the dietary survey, 1, 2, 3, 4 and 7 days and laboratory technique 
zinc assessment method to determine the concentration of zinc in whole blood, atomic 
absorption spectrophotometry (AAS) (1), inductively coupled plasma mass spectrometry or 
atomic emission spectrometry (ICP-MS or ICP-AES) (2). 
Multivariate meta‐regressions were used to examine the covariates that had a significant 
influence on heterogeneity in univariate analysis. Covariates showing collinearity were 
removed from the final multivariate model. In addition, to examine how much of the 
heterogeneity was accounted for by the studied covariates, the adjusted R2 was calculated 
by comparing the baseline value of the heterogeneity variance obtained from the empty 
regression model, with the heterogeneity variance from the meta-regression after the 
covariate was added. Finally, stratified analysis was also used in order to assess possible 
causes of heterogeneity. 
Random effects meta-regressions were also used to examine whether any covariate had 
influence on the results. Bubble plots were created to show a relevant influence of a single 
continuous covariate on MDs in a meta-regression model. This graph represents the fitted 
regression line together with circles representing the estimates from each study, sized 
according to the precision of each estimate (the inverse of its within-study variance). 
Publication bias was investigated by visual inspection of funnel plots and quantitatively 
assessed using Egger’s [30] and Begg’s [31] tests.  
To test the influence of each study on the overall effect size, sensitivity analysis was 
conducted using Leave-One-Out method, that is removing one study each time and 
repeating the analysis [32]. All analyses were conducted in STATA statistical software 
(Version 12.0. STATA Corp., College Station, Texas, USA). 
Results 
The search strategy initially yielded 11,156 publications (Figure 1), of which 11 were 
included in the meta-analyses [15–20,22,23,33–35]. Nine results were included for the final 
meta-analysis that compared the dietary zinc intake in diabetic and non-diabetic subjects 
[19,20,22,23,33,34]. Meanwhile, six results were included in the meta-analysis that 
compared the concentration of zinc in whole blood in diabetic and non-diabetic subjects [15–
18,35]. The characteristics of the included studies are summarized in Table 1. 
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Meta-analysis of dietary zinc intake and T2DM data: Four studies selected for the dietary 
zinc intake meta-analysis were carried out in western countries (England [33], Brazil [20,22] 
and Australia [23]) and two in eastern countries (Korea [34] and Iraq [19]). All those studies 
had cross-sectional design [20,22,23,33,34], except a clinical trial performed by Al-Maroof 
and Al-Sharbatti in Iraq [19]. However, data extracted for our systematic review and meta-
analysis were collected at one time point, before intervention, so we were able to include 
baseline data from the study of Al-Maroof and Al-Sharbatti. Dietary zinc intake was 
determined using  two different survey methods, 24-hour dietary recall, used by both studies 
from western countries [19,34], and dietary record administered for two [23], three [22], four 
[20] or seven [33] days. Two studies recruited only women [23,34], while the other studies 
collected data in men and women [19,20,22,33]. Known duration of diabetes was 7.20±7.26 
years for diabetic participants, taking into account five of the six selected studies 
[19,20,22,23,34]. 
Meta-analysis of the concentration of zinc in whole blood and T2DM: Two studies selected 
for this meta-analysis (Table 2) were conducted in western countries (Austria [17] and Italy 
[18]), and three in eastern countries (Pakistan [15,35] and China [16]). Their design was 
cross-sectional, and the laboratory method used for tissue zinc analysis was AAS [15,17,35] 
or ICP-MS or ICP-AES [16,18]. The time since diagnosis of T2DM in patients ranged from 8 
to 20 years. The quality of selected studies was moderate, according to the STROBE 
Statement [26]. 
An overall pooled MD of -0.40 (95% CI: -1.59 to 0.79) was observed in the meta-analysis 
that investigated the dietary zinc intake in diabetic cases and healthy controls (Figure S1). 
Differences become significant (MD = -2.26; 95% CI: -3.49 to -1.02) when diabetes was 
associated with complications (Figure 2). Moderate heterogeneity was observed in this 
meta-analysis (I2 = 61.0%, P = 0.009), suggesting that 61% of the variability between studies 
was due to differences in dietary zinc intake and 29% due to sampling variation. To examine 
how much of the heterogeneity was accounted for by the presence of complications 
associated with diabetes, we used the adjusted R2 (Tabla 2), and observed that this 
explained heterogeneity largely (R2 = 92.20%; I2 residual = 0.00%). Thus, when we stratified 
by the presence of complications associated with diabetes, we observed that heterogeneity 
was reduced to 0.0% in the group without complications, and to 11.9% in the group with 
complications (Figure 2). In addition to complications associated with diabetes, duration of 
diabetes contributed significantly to the heterogeneity (R2 = 100.00%; I2 residual = 0.00%). 
Through meta-regression (Figure 3), we found that for each year since the diagnosis of 
diabetes the mean difference in dietary zinc intake between diabetics and non-diabetics 
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subjects seemed to increase [MD (dietary zinc intake) = 1.67 + (-0.37) x (duration of 
diabetes in years)]. 
In the meta-analysis that compared the concentrations of zinc in whole blood in diabetic and 
non-diabetic subjects, a pooled MD of -216.80 (95% CI: -359.42 to -74.19) was found 
(Figure S2). High heterogeneity was found in this meta-analysis (I2 = 97.7%, P < 0.001). 
However, stratified analyses by geographic area, western vs. eastern countries, reduced 
considerably the heterogeneity (I2 = 47.1%, P < 0.129) and (I2 = 69.3%, P < 0.071), 
respectively (Figure 4). Identical results were obtained when we stratified by studies which 
had been matched by age vs. not matched by age (Figure S3), had similar aged groups in 
cases and controls vs. those which had different ages groups (Figure S4), and with sample 
size higher vs. lower than 150 participants (Figure S5). Furthermore, these stratified analysis 
explained 96.24% of heterogeneity R2 = 96.24%; I2 residual = 55.19%). In this meta-
analysis, duration of diabetes had also an important influence on heterogeneity (R2 = 
96.16%; I2 residual = 58.23%). We have also observed that for each year since the 
diagnosis of diabetes, the concentration of zinc in whole blood (1µg/dL = 0.0483µmol/L) is 
reduced in diabetic patients regarding healthy controls. This data is presented as a bubble 
plot (Figure 5), and expressed in the equation of the regression line [MD (concentration of 
zinc in blood) = 732.61 + (-77.88303) x (duration of diabetes in years)]. Finally, sample size 
also had an impact on the results (Figure 6) [MD (concentration of zinc in whole blood) = 
371.84 + (-3.44) x (sample size)]. 
By visual inspection, an overall symmetry of the funnel plots was observed for all meta-
analyses (Figures S6 and S7). This was confirmed by the Egger’s (P=0.553 for meta-
analysis of dietary zinc intake, and P= 0.768 for meta-analysis of the concentration of zinc in 
whole blood) and Begg’s (P=1.000 for both meta-analyses) tests which were not significant, 
indicating the absence of publication bias. In addition, neither of the two meta-analyses 
results were affected substantially after removing one study at a time and repeating the 
analysis. The combined result ranged between -0.70 (95% CI: -1.87 to 0.46), after removing 
the result of Rauscher et al. [33] in men, and -0.08 (95% CI: -1.35 to 1.19), after removing 
the study of Lee et al. [34] for the meta-analysis of dietary zinc intake. Meanwhile, for the 
meta-analysis of the concentration of zinc in whole blood, results ranged between -187.76 
(95% CI: -344.87 to -30.65), after removing the result of Kazi in women, and -264.86 (95% 
CI: -389.79 to -139.93), after removing the study of Ekmekcioglu [17]. 
Discussion and Conclusion 
Data from this systematic review, meta-analysis and meta-regression of observational 
studies suggests that there are significant differences in the concentration of zinc in whole 
9 
 
blood between diabetic patients and healthy subjects. In addition, the duration of diabetes 
appears to be associated with the concentration of zinc in whole blood, which is not 
explained by a lower of dietary zinc intake in diabetic patients. Only when T2DM is 
associated with complications, such as diabetic nephropathy in which dietary therapy is 
essential, differences in dietary zinc intake became significant. Changes in the concentration 
of zinc in whole blood may reflect changes in tissue zinc distribution and cellular zinc 
homeostasis in patients with diabetes, as was suggested by Chausmer in 1998 [36]. 
Our results did not show significant differences in dietary zinc intake between diabetic and 
non-diabetic subjects. However, the combined result showed some evidence of 
heterogeneity (I2 = 61.0%). When we stratified by the presence of complications associated 
with diabetes, we found significant differences in the subgroup with complications (MD = -
2.26; 95% CI: -3.49 to -1.02), and low heterogeneity (I2 = 11.9%). Meanwhile, in the 
subgroup without complications no significant differences in dietary zinc intake between 
groups, and an undetectable heterogeneity (I2 = 0.0%) were found (Table 2). Only two 
studies reported complications associated to T2DM in diabetic participants [20,34]. The 
study of Batista et al. was conducted on diabetic subjects with chronic kidney disease due 
mainly to diabetic nephropathy [20]. Meanwhile, Lee et al. reported that only 24.0% of T2DM 
cases did not have associated complications, 36.0% presented diabetic nephropathy, and 
10% coronary heart disease [34]. In patients with diabetic nephropathy, diet therapies, such 
as protein restriction are commonly advised [37,38]. It is well known that zinc intake 
correlates directly with protein intake, as these two nutrients share the same food sources 
[39]. This correlation was also observed in the study carried out by Batista et al. [20], 
supporting the role of advanced kidney disease as a cause of a lower dietary zinc intake in 
this patients. The change from not having to having complications associated with diabetes 
supposes a significant increment in MD of dietary zinc intake of 2.70 mg/day (MD = -2.70; 
95% CI: -4.48 to -0.93; P = 0.009). Thus, diabetic patients consume 2.70 mg/day less zinc 
than healthy controls when they have associated pathologies (Table 2). 
The duration of diabetes seems to have an influence on dietary zinc intake. We observed 
that stratified analysis by duration of diabetes (<8; ≥8 years) and (<5; 5-8; ≥8 years) reduced 
the heterogeneity considerably. In addition, when we conducted a meta-regression, 
introducing duration of diabetes as a continuous variable, we found that for each year since 
the diagnosis of T2DM, diabetics consume less zinc [MD (dietary zinc intake) = 1.67 + (-
0.37) x (duration of diabetes in years)] in their diet (Figure 3). However, this may be due to 
the inclusion of the studies where the diabetic patients had complications as described 
above. When these studies are excluded, no significant relationship or trend between the 
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duration of diabetes and the MD of dietary zinc intake was observed (MD = 0.07; 95% CI: -
2.79 to 2.94, P = 0.924). 
Variables, such as gender, geographic area, age or BMI, do not appear to have an impact 
on the results (Table 2), suggesting that dietary zinc intake is similar in diabetic and non-
diabetic subjects in all age ranges, in both genders, in normal weight or overweight, and in 
different populations. 
For all the above, the dietary zinc intake does not seem to explain the observed differences 
in the concentration of zinc in whole blood between diabetic and non-diabetic individuals. 
However, these differences (Figure S2) may not be reliable due to the very high 
heterogeneity observed (I2 = 97.7%). Stratified analysis by geographic area (Figure 4), as 
well as, matched controls (Figure S3), older group (Figure S4) or sample size (Figure S5), 
significantly reduced the heterogeneity to 47.1% and 69.3% in each subgroup (Table 3), 
demonstrating their influence on the differences in the concentration of zinc in whole blood, 
and making the result more plausible. 
We have also observed significant differences in the concentration of zinc in whole blood 
between cases and controls, but only in eastern countries (Figure 4), namely China [16] and 
Pakistan [15,35] (table 3). Studies conducted in  Austria [17] and Italy [18], did not show 
significant differences in the concentration of zinc in whole blood between cases and 
controls. Studies from eastern countries compared diabetic patients with age-matched 
healthy controls, whereas, studies from western countries recruited patients and controls 
with significantly different ages, which may explain differences in results found according to 
the geographic area. 
The influence of the duration of diabetes on the concentration of zinc in whole blood has 
also been examined (Figure 5). The results revealed that for each year since the onset of 
T2DM, the concentration of zinc in whole blood decreases compared to healthy subjects. 
This result is consistent with study conducted by Luo et al., who found that duration of 
diabetes was a key determinant of serum zinc levels [40], suggesting that the duration of 
diabetes may be associated with changes in zinc homeostasis. Drug therapy in diabetic 
patients could play a key role in the relationship between the duration of diabetes and the 
concentration of zinc in whole blood. Thus, it has been proposed that insulin treatment may 
normalised the tissue zinc concentration [9]. Unfortunately, this premise could not be 
assessed in our meta-analysis since data from selected studies was insufficient. Only two 
studies reported the use of insulin therapy in 40% [15] and 100% [35] of diabetic 
participants, and their whole blood zinc concentrations were significantly lower compared to 
11 
 
healthy controls. These data do not support the hypothesis, but further studies are needed to 
explore this in more detail. 
Some limitations to our study need to be considered. First, the relatively small number of 
studies included in both meta-analyses, despite the large number of articles obtained from 
the search (11,156). This is because the robust search strategy within the framework of the 
EURRECA Network of Excellence was conducted as part of a wider review process to 
identify studies assessing the effect of zinc on different outcomes, and was designed to 
avoid publication bias. In addition, we included non-English language journals, reducing any 
potential bias. Furthermore, standard tests and visual inspection of funnel plots in both meta-
analyses suggest that there is little evidence for publication bias. Second, the quality of the 
selected studies was moderate, according to the STROBE Statement [26]. After evaluating 
the influence of quality on results through stratified analyses and meta-regression, no 
significant impact on the effect size was observed in any of the meta-analyses. Furthermore, 
when the highest quality studies were combined to obtain a pooled MD, there was no 
detectable heterogeneity in either meta-analysis (0.0%), and the results were similar to the 
respective overall pooled MD (Tables 2 and 3). Third, since the overall analyses did not have 
a large sample size, the stratified analyses might have insufficient power to detect potential 
sources of heterogeneity. In order to correct this, we carried out, not only stratified analysis, 
but also random effects meta-regressions to examine whether any covariate had influence 
on the results. Fourth, the results showed an undetectable to moderate heterogeneity in both 
meta-analyses (Figures 2 and 4), which also contribute to the study validity. Finally, none of 
the selected studies for meta-analysis of zinc concentration reported whether or not the 
samples were collected from fasting participants. This could be a source of bias, however it 
is noteworthy that all the selected studies for this meta-analysis used whole blood samples 
to measure zinc concentration, thus avoiding possible biases caused by using different 
samples. 
The relationship between zinc and glucose metabolism has been evidenced in numerous 
studies. Zinc participates in the synthesis, storage, secretion, action of insulin and 
translocation of insulin into the cells [1–3], as well as translocation of GLUT4 to the cell 
surface for glucose transport into the insulin responsive cells [4]. However, the underlying 
biological mechanism whereby T2DM could have an impact on zinc homeostasis has not 
been elucidated. Recently, the importance of the cellular zinc transport system in T2DM has 
been highlighted [41,42]. A study conducted by Chu et al., found differences in gene 
expressions for most zinc transporters analysed, such as ZnT1, ZnT5, ZnT7, ZIP1, ZIP3, 
ZIP7, ZIP10, metallothionein-1A and metallothionein-2A. A lower gene expression in all 
these transporters was observed in diabetics compared to controls, suggesting disturbances 
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T2DM-associated zinc dyshomeostasis at the cellular level [11]. This alteration on zinc 
metabolism may explain differences in the concentration of zinc in whole blood in diabetic 
subjects observed in the present systematic review, meta-analysis and meta-regression. 
Nevertheless, the preliminary results of another systematic review and meta-analysis of 
more than 73 papers conducted by our group reveals a lack of significant difference in zinc 
status, measured using serum or plasma zinc concentration, between diabetic patients and 
healthy controls. A possible explanation to both results could be that T2DM may not induce a 
lower zinc status compared with non-diabetic subjects, but has a negative impact on zinc 
homeostasis that would lead to differences in tissue zinc concentrations, such as blood. 
In conclusion, data from this systematic review, meta-analysis and meta-regression of 
observational studies suggests that there are significantly lower concentration of zinc in 
whole blood of diabetic patients compared with non-diabetic subjects, which is not explained 
by lower dietary zinc intakes. Only when T2DM is associated with complications, such as 
diabetic nephropathy, in which dietary therapy is essential, a lower dietary zinc intake is 
observed. However, the duration of diabetes could have a significant impact on whole blood 
zinc concentration. Additional research is required to elucidate the possible underpinning 
mechanisms. 
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Figure 1. Flowchart of the search for studies and the selection process. 
Figure 2. Forest plot of pooled mean difference of dietary zinc intake according to the 
presence of complications associated to diabetes. Squares represent the mean difference 
(MD) for each study and the size of the square reflects the study-specific statistical weight. 
Horizontal lines indicate the 95% CI of each study. Diamond represents the combined MD 
estimate with corresponding 95 % CI. I-squared and p-value inform about heterogeneity 
among studies. 
Figure 3. Bubble plot with a fitted meta-regression line of the mean difference in dietary zinc 
intake and duration of diabetes. Circles are sized according to the precision of each estimate 
(the inverse of its within-study variance) with larger bubbles for more precise estimates. 
Figure 4. Forest plot of pooled mean difference of concentration of zinc in whole blood 
according to geographic area. Squares represent the mean difference (MD) for each study 
and the size of the square reflects the study-specific statistical weight. Horizontal lines 
indicate the 95% CI of each study. Diamond represents the combined MD estimate with 
corresponding 95 % CI. I-squared and p-value inform about heterogeneity among studies. 
Figure 5.Bubble plot with a fitted meta-regression line of the mean difference in 
concentration of zinc in whole blood and duration of diabetes. Circles are sized according to 
the precision of each estimate (the inverse of its within-study variance) with larger bubbles 
for more precise estimates. 
Figure 6. Bubble plot with a fitted meta-regression line of the mean difference in 
concentration of zinc in whole blood and sample size of the studies. Circles are sized 
according to the precision of each estimate (the inverse of its within-study variance) with 
larger bubbles for more precise estimates. 
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Appendix A. Supplementary data 
Table S1. Evaluation of the quality based on the STROBE Statement. 
Figure S1. Forest plot of pooled mean difference of dietary zinc intake. Squares represent 
the mean difference (MD) for each study and the size of the square reflects the study-
specific statistical weight. Horizontal lines indicate the 95% CI of each study. Diamond 
represents the combined MD estimate with corresponding 95 % CI. I-squared and p-value 
inform about heterogeneity among studies. 
Figure S2. Forest plot of pooled mean difference of concentration of zinc in whole blood. 
Squares represent the mean difference (MD) for each study and the size of the square 
reflects the study-specific statistical weight. Horizontal lines indicate the 95% CI of each 
study. Diamond represents the combined MD estimate with corresponding 95 % CI. I-
squared and p-value inform about heterogeneity among studies. 
Figure S3. Forest plot of pooled mean difference of concentration of zinc in whole blood 
according to control matched (No matched, matched by age). Squares represent the mean 
difference (MD) for each study and the size of the square reflects the study-specific 
statistical weight. Horizontal lines indicate the 95% CI of each study. Diamond represents 
the combined MD estimate with corresponding 95 % CI. I-squared and p-value inform about 
heterogeneity among studies. 
Figure S4. Forest plot of pooled mean difference of concentration of zinc in whole blood 
according to age in diabetic and non-diabetic groups (same age, different age). Squares 
represent the mean difference (MD) for each study and the size of the square reflects the 
study-specific statistical weight. Horizontal lines indicate the 95% CI of each study. Diamond 
represents the combined MD estimate with corresponding 95 % CI. I-squared and p-value 
inform about heterogeneity among studies. 
Figure S5. Forest plot of pooled mean difference of concentration of zinc in whole blood 
according to sample size (<150, >150). Squares represent the mean difference (MD) for 
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each study and the size of the square reflects the study-specific statistical weight. Horizontal 
lines indicate the 95% CI of each study. Diamond represents the combined MD estimate with 
corresponding 95 % CI. I-squared and p-value inform about heterogeneity among studies. 
Figure S6. Funnel plots of publication biases of studies included in the meta-analysis of 
dietary zinc intake. Y-axis stands for the standard error of the mean difference of dietary zinc 
intake and X-axis stands for the mean difference of dietary zinc intake. Each dot stands for 
an individual study. Asymmetric funnel plot indicates a publication bias. 
Figure S7. Funnel plots of publication biases of studies included in the meta-analysis of 
concentration of zinc in whole blood. Y-axis stands for the standard error of the mean 
difference of concentration of zinc in whole blood and X-axis stands for the mean difference 
of concentration of zinc in whole blood. Each dot stands for an individual study. Asymmetric 
funnel plot indicates a publication bias.  
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Table 1. Characteristics of studies included in the meta-analyses and meta-regressions on dietary zinc intake and whole blood zinc concentration in diabetic and non-diabetic subjects. 
Author, year Location Gender 
Age (years) in 
diabetic subjects 
(Mean±SD) 
Age (years) in non-
diabetic subjects 
(Mean±SD) 
Sample 
size 
T2DM 
(n) 
Control 
Matched 
T2DM duration in 
years (Mean±SD) 
Zinc assessment 
method 
Dietary (mg/day) 
or whole blood 
(µmol/L) zinc in 
diabetics 
(Mean±SD) 
Dietary (mg/day) 
or whole blood 
(µmol/L) zinc in 
non-diabetics 
(Mean±SD) 
Studies of dietary zinc intake 
Rauscher, 1997 England 
Women 
/ Men 
Range: 49-72                           
63.0  
Range: 50-77         61.5  20 10 
Age, sex & 
weight 
Not Showed 7-day dietary record 
11.8±2.2 10.3±2.6 
Men 
Range: 49-71                    
61.0  
Range: 50-71          58.0  10 5 13.2±1.5 11.1±2.5 
Women 
Range: 60-72                     
65.0  
Range: 60-77              
65.0  
10 5 10.3±1.8 9.5±2.5 
Lee, 2005 Korea Women 57.9±6.9 56.3±7.9 119 50 No 8.0±6.5 24h-hour recall 6.2±2.7 8.0±3.2 
Al-Maroof, 2006 Iraq 
Women 
/ Men 
54.6±9.2 39.0±9.3 234 101 No 5.1±6.0 24h-hour recall 12.2±4.6 12.4±4.4 
Batista, 2006 Brazil 
Women 
/ Men 
61.1±8.1 52.9±9.7 
53 33 
No 16.3±8.8 4-day dietary record 
6.5±4.2 9.4±5.0 
Men 24 16 7.5±3.8 11.6±4.5 
Women 29 17 4.6±2.7 8.1±5.2 
de Sousa Lima, 
2011 
Brazil 
Women 
/ Men 
Range: 25-59 46.0±7.4 37.2±8.6 
73 36 
No 4.0±2.4 3-day dietary record 
12.9±5.8 11.7±4.7 
Men 22 12 16.9±7.3 14.9±6.5 
Women 51 24 10.9±3.5 10.5±3.4 
Foster, 2012 Australia Women 
Range: 48.3-79 
63.8±8.8 
Range: 21.4-65.6 
39.4±13.8 
40 20 No 6.5±5.2 2-day dietary record 12.8±5.3 11.6±3.8 
Studies of concentrations of zinc in blood 
Ekmekcioglu, 2001 Austria 
Not 
Showed 
63.8±11.0 70.5±12.4 103 53 No Not Showed EAAS 25.7±4.7 24.9±5.8 
Kazi, 2008 Pakistan 
Women 
/ Men 
Range: 45-75 Range: 45-75 
423 257 
Age Range: 8-20 AAS 
31.3±10.6 47.9±7.5 
Men 217 137 29.9±10.7 46.9±7.2 
Women 206 120 32.7±10.4 48.9±7.7 
Afridi, 2009 Pakistan Women Range: 30-40 Range: 30-40 182 89 Age Range: 10-15 F/EAAS 46.9±6.3 60.4±7.2 
Chen, 2012 China 
Not 
Showed 
Range: 25- >50 Range: 25- >50 158 53 Age Not Showed ICP- AES 43.1±31.4 60.4±48.3 
Forte, 2013 Italy 
Women 
/ Men 
Mean±SD: 68.4±11.2 Mean±SD: 57.2±18.0 127 68 No 
Mean±SD: 
10.2±8.6 
ICP-MS 30.5±4.8 32.6±8.2 
T2DM (Type 2 Diabetes Mellitus), SD (Standard deviation), AAS (Atomic Absorption Spectrophotometry), F/EAAS (Flame/Electrothermal Atomic Absorption Spectroscopy),  EAAS (Electrothermal Atomic Absorption Spectroscopy), ICP- AES 
(Inductively Coupled Plasma Atomic Emission Spectrometry), ICP- MS (Inductively Coupled Plasma Mass Spectrometry). 
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Table 2. Stratified analysis and meta-regression for mean difference of dietary zinc intake in diabetic and non-diabetic subjects. 
 
Subgroup 
Studies 
(n) 
Mean difference 
(95% CI) 
Heterogeneity Meta-regression 
 
I2 (%) P-value 
Regression coefficients 
(95% CI) 
P-value Tau2 
I2 residual 
(%) 
Adjusted R2  
(%)  
Geographic area 
 
     Eastern 2  -1.01 (-2.54; 0.53) 73.8% 0.051 
 -0.91 (-4.43; 2.60) 0.559 2.25 59.95% -19.37%  
     Western 7  -0.10 (-1.79; 1.59) 56.1% 0.034 
 
Continent 
 
     America (1) 4  -1.48 (-4.24; 1.27) 63.7% 0.041 
1.01 (-0.18; 2.20) 0.085 1.06 52.24% 43.60% 
 
     Asia (2) 2  -1.01 (-2.54; 0.53) 73.8% 0.051 
 
     Oceania (3) 1 1.20 (-1.66; 4.06)  -  - 
 
     Europe (4) 2 1.49 (-0.37; 3.34) 0.0% 0.493 
 
Quality 65 
 
     <65 5  -1.53 (-3.21; 0.15) 55.4% 0.062 
2.21 (-0.28; 4.70) 0.074 0.91 41.99% 51.73%  
     ≥65 4 0.41 (-0.56; 1.38) 3.1% 0.377 
 
Quality 70 
 
     <70 7  -0.65 (-2.27; 0.96) 66.0% 0.007 
0.99 (-2.80; 4.77) 0.558 2.43 62.04% -28.84%  
     ≥70 2 0.00 (-1.08; 1.08) 0.0% 0.374 
 
Gender 
 
     Men (1) 3  -0.09 (-4.44; 4.27) 74.6% 0.019 
 -0.52 (-5.19; 4.16) 0.796 3.55 67.24% -25.67%  
     Women (2) 5  -0.60 (-2.16; 0.95) 61.7% 0.034 
 
     Both genders 1  -0.20 (-1.37; 0.97)  -  -  -  -  -  -  - 
 
Age of diabetics (years) 
 
     40-50 2 0.56 (-1.25; 2.36) 0.0% 0.606 
 -0.39 (-2.64; 1.87) 0.698 2.60 65.87% -37.75% 
 
     50-60 2  -1.01 (-2.54; 0.53) 73.8% 0.051 
 
     60-70 5  -0.51 (-2.89; 1.88) 69.3% 0.011 
 
Age of diabetics 50 (years) 
 
     <50 2 0.56 (-1.25; 2.36) 0.0% 0.606 
 -1.41 (-5.70; 2.89) 0.465 2.27 62.33% -20.55%  
     ≥50 7  -0.64 (-2.02; 0.74) 67.2% 0.005 
 
Age of diabetics 60 (years) 
 
     <60 4  -0.55 (-1.80; 0.70) 55.2% 0.082 
 -0.05 (-3.51; 3.41) 0.974 2.64 64.51% -39.68%  
     ≥60 5  -0.51 (-2.89; 1.88) 69.3% 0.011 
 
Age of non-diabetics (years) 
 
     30-40 4 0.15 (-0.78; 1.07) 0.0% 0.723 
 -0.52 (-1.96; 0.92) 0.418 2.17 58.60% -15.08% 
 
     50-60 4  -1.62 (-3.98; 0.75) 73.5% 0.010 
 
     60-70 1 0.80 (-1.90; 3.50)  -  - 
 
Age of non-diabetics 50 (years) 
 
23 
 
     <50 4 0.15 (-0.78; 1.07) 0.0% 0.723 
 -1.57 (-4.65; 1.51) 0.267 1.86 54.22% 1.61%  
     ≥50 5  -1.13 (-3.16; 0.89) 71.4% 0.007 
 
Age difference between diabetics and non-diabetics  (years) 
 
     <5 3 0.16 (-2.43; 2.76) 78.7% 0.009 
0.02 (-2.15; 2.20) 0.982 2.70 62.83% -43.24% 
 
     5-15 4  -1.48 (-4.24; 1.27) 63.7% 0.041 
 
     ≥15 2 0.00 (-1.08; 1.08) 0.0% 0.374 
 
Age difference between diabetics and non-diabetics II  (years) 
 
     <10 7  -0.65 (-2.27; 0.96) 66.0% 0.007 
0.99 (-2.80; 4.77) 0.558 2.43 62.04% -28.84%  
     ≥10 2 0.00 (-1.08; 1.08) 0.0% 0.374 
 
Older group 
 
     Same age (1) 3 0.16 (-2.43; 2.76) 78.7% 0.009 
 -0.76 (-4.26; 2.74) 0.623 2.71 64.32% -43.85%  
     Different age (2) 6  -0.62 (-2.12; 0.88) 51.1% 0.069 
 
BMI category in diabetics 
 
     Normal weight (18.5-24.9 kg/m2) 5  -1.13 (-3.16; 0.89) 71.4% 0.007 
1.57 (-1.51; 4.65) 0.267 1.86 54.22% 1.61%  
     Overweight (25.0-29.9 kg/m2) 4 0.15 (-0.78; 1.07) 0.0% 0.723 
 
BMI category in non-diabetics 
 
     Normal weight (18.5-24.9 kg/m2) 5  -0.03 (-1.57; 1.51) 55.1% 0.064 
 -1.11 (-4.47; 2.24) 0.459 2.73 65.44% -44.77%  
     Overweight (25.0-29.9 kg/m2) 4  -1.10 (-3.51; 1.30) 73.6% 0.010 
 
Duration of diabetes (years) 
 
     <8 4 0.15 (-0.78; 1.07) 0.0% 0.723 
 -2.24 (-4.00; -0.48) 0.022 0.00 0.00% 100.00%  
     ≥8 3  -2.26 (-3.49; -1.02) 11.9% 0.321 
 
     No data 2 1.49 (-0.37; 3.34) 0.0% 0.493  -  -  -  -  - 
 
Complications 
 
     Without complications of diabetes 6 0.41 (-0.41; 1.24) 0.0% 0.640 
 -2.70 (-4.48; -0.93) 0.009 0.15 0.00% 92.20%  
     With complications of diabetes 3  -2.26 (-3.49; -1.02) 11.9% 0.321 
 
Sample size 
 
     <100 7  -0.10 (-1.79; 1.59) 56.1% 0.034 
 -0.91 (-4.43; 2.60) 0.559 2.25 59.95% -19.37%  
     ≥100 2  -1.01 (-2.54; 0.53) 73.8% 0.051 
 
Matched 
 
     No matched 2  -0.89 (-2.14; 0.36) 58.1% 0.026 
2.36 (-1.10; 5.81) 0.151 1.10 52.69% 42.20%  
     Matched by age, gender & weight 7 1.49 (-0.37; 3.34) 0.0% 0.493 
 
Dietary survey method 
 
     24-hour dietary recall 2  -1.01 (-2.54; 0.53) 73.8% 0.051 
0.91 (-2.60; 4.43) 0.559 2.25 59.95% -19.37%  
     Dietary record 7  -0.10 (-1.79; 1.59) 56.1% 0.034 
 
Days of dietary survey 
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     24-hour dietary recall (1) 2  -1.01 (-2.54; 0.53) 73.8% 0.051 
0.26 (-0.45; 0.97) 0.413 1.82 58.44% 3.60% 
 
     2-day dietary record (2) 1 1.20 (-1.66; 4.06)  -  - 
 
     3-day dietary record (3) 2 0.56 (-1.25; 2.36) 0.0% 0.606 
 
     4-day dietary record (4) 2  -3.76 (-6.17; -1.36) 0.0% 0.808 
 
     7-day dietary record (7) 2 1.49 (-0.37; 3.34) 0.0% 0.493 
 
BMI (Body Mass Index). 
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Table 3. Stratified analysis for mean difference of the whole blood zinc concentration in diabetic and non-diabetic subjects. 
Subgroup 
Studies 
(n) 
Mean difference (95% CI) 
Heterogeneity Meta-regression 
I2 (%) 
P-
value 
Regression coefficients 
(95% CI) 
P-value Tau2 
I2 residual 
(%) 
Adjusted R2  
(%) 
Geographic area 
     Eastern 4  -320.83 (-361.46; -280.19) 47.1% 0.129 
 -309.20 (-408.99; -209.42) 0.001 1012 55.19% 96.24% 
     Western 2  -12.41 (-70.89; 46.08) 69.3% 0.071 
Continent 
     Europe 2  -12.41 (-70.89; 46.08) 69.3% 0.071 
 -309.20 (-408.99; -209.42) 0.001 1012 55.19% 96.24% 
     Asia 4  -320.83 (-361.46; -280.19) 47.1% 0.129 
Quality 50 
     <50 3  -191.61 (-438.19; 54.97) 98.0% <0.001 
 -55.64 (-479.08; 367.81) 0.734 32234 97.94% -19.72% 
     ≥50 3  -243.57 (-440.95; -46.19) 97.9% <0.001 
Quality 55 
     <55 4  -146.24 (-316.36; 23.89) 97.3% <0.001 
 -202.89 (-547.55; 141.77) 0.178 18048 96.42% 32.96% 
     ≥55 2  -343.86 (-379.36; -308.37) 0.0% 0.649 
Gender 
     Men (1) 1  -351.80 (-401.08; -302.52)  -  - 
46.41 (-571.35; 644.17) 0.515 972 63.59% 0.18% 
     Women (2) 2  -305.39 (-359.40; -251.38) 63.6% 0.097 
     Both genders 1  -43.73 (-93.14; 5.67)  -  -  -  -  -  -  - 
     No data 2  -148.21 (-512.01; 215.58) 87.2% 0.5%  -  -  -  -  - 
Age of diabetics (years) 
     30-40 1  -280.00 (-320.73; -239.27)  -  - 
88.59 (-111.75; 288.93) 0.254 23307 97.58% 20.04%      50-60 2  -343.86 (-379.36; -308.37) 0.0% 0.649 
     60-70 2  -12.41 (-70.89; 46.08) 69.3% 0.071 
     No data 1  -358.00 (-617.29; -98.71)  -  -  -  -  -  -  - 
Age of diabetics 50 (years) 
     <50 1  -280.00 (-320.73; -239.27)  -  - 
101.57 (-580.72; 783.86) 0.668 36305 98.43% -24.55% 
     ≥50 4  -178.44 (-369.42; 12.55) 98.4% <0.001 
     No data 1  -358.00 (-617.29; -98.71)  -  -  -  -  -  -  - 
Age of non-diabetics (years) 
     30-40 1  -280.00 (-320.73; -239.27)  -  - 
73.98 (-103.31; 251.27) 0.276 24367 97.52% 16.41%      50-60 3  -243.57 (-440.95; -46.19) 97.9% <0.001 
     70-80 1 16.01 (-26.58; 58.13)  -  - 
     No data 1  -358.00 (-617.29; -98.71)  -  -  -  -  -  -  - 
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Age of non-diabetics 50 (years) 
     <50 1  -280.00 (-320.73; -239.27)  -  - 
101.57 (-580.72; 783.86) 0.668 36305 98.43% -24.55%      ≥50 4  -178.44 (-369.42; 12.55) 98.4% <0.001 
     No data 1  -358.00 (-617.29; -98.71)  -  - 
Older group II 
     Same age (1) 4  -320.83 (-361.46; -280.19) 47.1% 0.129 
 -309.20 (-408.99; -209.42) 0.001 1012 55.19% 96.24% 
     Different age (2) 2  -12.41 (-70.89; 46.08) 69.3% 0.071 
Duration of diabetes (years) 
     <13 2  -162.30 (-393.83; 69.24) 98.1% <0.001 
 -180.84 (-692.57; 330.88) 0.268 13550 96.19% 31.12% 
     ≥13 2  -343.86 (-379.36; -308.37) 0.0% 0.649 
     No data 2  -148.21 (-512.01; 215.58) 87.2% 0.005  -  -  -  -  - 
Sample size 
     <150 2  -12.41 (-70.89; 46.08) 69.3% 0.071 
 -309.20 (-408.99; -209.42) 0.001 1012 55.19% 96.24% 
     ≥150 4  -320.83 (-361.46; -280.19) 47.1% 0.129 
Matched 
     No matched 2  -12.41 (-70.89; 46.08) 69.3% 0.071 
 -309.20 (-408.99; -209.42) 0.001 1012 55.19% 96.24%      Matched by age, gender 
& weight 
4  -320.83 (-361.46; -280.19) 47.1% 0.129 
Zinc assessment method 
     ASS 4  -237.46 (-411.56; -63.35) 98.3% <0.001 
69.65 (-389.57; 528.86) 0.695 31017 97.80% -15.21% 
     ICP 2  -174.03 (-477.49; 129.42) 81.6% 0.020 
AAS (Atomic Absorption Spectrophotometry), ICP (Inductively coupled plasma), EAAS (Electrothermal Atomic Absorption Spectroscopy). 
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